Reverb Therapeutics Raises USD $12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify•R™ Platform
February 19, 2025
Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma
February 12, 2025
Statement from The Multiple Myeloma Research Foundation (MMRF) on Distinguished Business Leader Richard Parsons
December 27, 2024
Sarclisa (isatuximab): A New Option for Patients With Newly Diagnosed Myeloma Not Eligible for Transplant
December 23, 2024
MMRF Patient Navigator Q&A: Nursing Insights From the NCCN and JADPRO Annual Meetings
December 18, 2024
Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
December 18, 2024
Multiple Myeloma Research Foundation Partners with Family Reach to Deliver Critical Financial Support to Multiple Myeloma Patients and their Families
December 11, 2024
Multiple Myeloma Research Foundation (MMRF) Programs Power New Insights into High-Risk Multiple Myeloma at the 66th American Society of Hematology Annual Meeting
December 6, 2024
The Multiple Myeloma Research Foundation (MMRF) Announces the First Patient Enrolled in its Horizon Clinical Trials Program to Accelerate the Identification of Optimal Treatment Strategies for Multiple Myeloma
December 4, 2024
Meet Elizabeth Bohannon, the Spirit of Hope Honoree for the MMRF Walk/Run: San Francisco
December 1, 2024
Meet Team Dial, Participating in Memory of Pastor Steven Dial Sr., MMRF 2024 Walk/Run: Atlanta Spirit of Hope Honoree
October 17, 2024
Multiple Myeloma Research Foundation (MMRF) Presents New Data from Multiple Myeloma Research Programs at the 21st International Myeloma Society Annual Meeting
September 25, 2024
Meet Susan Speer, the Spirit of Hope Honoree for the Inaugural MMRF Walk/Run: Houston
September 11, 2024
Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor
August 26, 2024
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers
August 19, 2024
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM
August 6, 2024
Myeloma Investment Fund Invests in Envisagenics, A.I.-Driven Biotechnology Company
July 29, 2024
Meet Team Papa JJ (In honor of Douglas J.J. Peters), MMRF 2024 Walk/Run: Washington, D.C. Spirit of Hope Honoree
July 25, 2024
Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR T-Cell Technologies
July 11, 2024
Discovering new biology and vulnerabilities in high-risk disease from the MMRF CoMMpass study
July 2, 2024
Meet Dennis McClure MMRF 2024 Walk/Run: Dallas Spirit of Hope Honoree and member of the North Texas Myeloma Support Group (NTMSG)
June 6, 2024
Meet Team No Fear Warrior In honor of Ophire Jericho, MMRF 2024 Walk/Run: Tampa Spirit of Hope Honoree
May 16, 2024
FDA’s Accelerated Approval Pathway: MRD as an Intermediate Endpoint in Multiple Myeloma Trials
April 18, 2024
Answers to FAQs from our 2/14/24 webinar on bispecific antibodies in multiple myeloma
February 21, 2024
Meet team “Richard’s Rangers” in honor of Richard A. Englander MMRF 2024 Walk/Run: Philadelphia Spirit of Hope Honoree
February 5, 2024
MMRF Research Update: Key Study Looks to CoMMpass to Inform a New Prognostic Model
January 23, 2024
Meet Christine’s Crusaders, MMRF 2024 Walk/Run: Atlanta Spirit of Hope Honoree
January 17, 2024
Meet MaryLee Millard, MMRF 2024 Walk/Run: San Francisco Spirit of Hope Honoree
January 17, 2024
Answers to FAQs from our 12/20/23 webinar on Health Equity in Multiple Myeloma
December 22, 2023
Data from Multiple Myeloma Research Foundation (MMRF) research programs fuel advances presented at the 65th American Society of Hematology Annual Meeting
December 7, 2023
Multiple Myeloma Research Foundation (MMRF) Announces First Recipients of Scholars Program Awards, a Critical Step in Improving Diversity and Inclusion in Multiple Myeloma Research
November 30, 2023
Myeloma Investment Fund Invests in Reverb Therapeutics to Support Debut of its Amplifier™ Platform for Redirecting Endogenous Cytokines
November 15, 2023
The Multiple Myeloma Research Foundation Announces $21M Grant Program to Support Multicenter Translational Research Networks
November 2, 2023
Answers to FAQs from our 10/11/23 webinar on non-BCMA-Targeted Bispecific Antibodies
October 16, 2023
The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)
October 5, 2023
